Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Who Have Received Prior Therapy With an LHRH Agonist.

NCT00945477 is registered in ClinicalTrials.gov with Illinois CancerCare, P.C. as lead sponsor.

NCT NCT00945477
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00945477 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Who Have Received Prior Therapy With an LHRH Agonist.
Lead sponsor
Illinois CancerCare, P.C.
Phase
Phase 2
Overall status
Terminated
Start date
July 31, 2009
Completion date
October 31, 2012
Enrollment
11 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer